Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Osteoarthritis of the Knee.

X
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Osteoarthritis of the Knee.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lacosamide (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Schwarz Pharma AG; UCB
  • Most Recent Events

    • 29 Sep 2009 UCB added as trial affiliate and sponsor, actual patient number changed from 193 to 194 as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Actual patient number (193) added as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Planned end date changed from 1 Nov 2007 to 1 Jan 2008 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top